CO6311040A2 - CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS - Google Patents

CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS

Info

Publication number
CO6311040A2
CO6311040A2 CO10148450A CO10148450A CO6311040A2 CO 6311040 A2 CO6311040 A2 CO 6311040A2 CO 10148450 A CO10148450 A CO 10148450A CO 10148450 A CO10148450 A CO 10148450A CO 6311040 A2 CO6311040 A2 CO 6311040A2
Authority
CO
Colombia
Prior art keywords
dengue virus
reached
detection
antigen
binding molecule
Prior art date
Application number
CO10148450A
Other languages
Spanish (es)
Inventor
Kumar Sil Bijon
yun ying Tan
Original Assignee
Mp Biomedicals Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mp Biomedicals Asia Pacific Pte Ltd filed Critical Mp Biomedicals Asia Pacific Pte Ltd
Publication of CO6311040A2 publication Critical patent/CO6311040A2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona una prueba en punto de atención (PPDA) para detectar a un sujeto que ha tenido una exposición a un virus del dengue o un pariente inmunológico del mismo o que ha alcanzado algún nivel de inmunidad contra un antígeno del virus del dengue.El método se predica en parte sobre la detección de una molécula de enlace que es específica para un virus del dengue o un pariente inmunológico del mismo. La PPDA comprende poner en contacto una muestra biológica del sujeto con una mezcla de componentes inmunogénicos específicos del virus del dengue; y determinar la presencia de un complejo que se forma entre una molécula de enlace presente en la muestra biológica y un componente inmunogénico específico del virus del dengue; y caracterizar la molécula de enlace presente en el complejo con un anticuerpo contra la molécula de enlace conjugada con oro coloidal usando la tecnología de flujo inverso.The present invention provides a point-of-care test (PPDA) to detect a subject who has had an exposure to a dengue virus or an immunological relative thereof or who has reached some level of immunity against a dengue virus antigen. The method is predicated in part on the detection of a binding molecule that is specific for a dengue virus or an immunological relative thereof. PPDA comprises contacting a biological sample of the subject with a mixture of specific immunogenic components of dengue virus; and determining the presence of a complex that is formed between a binding molecule present in the biological sample and a specific immunogenic component of dengue virus; and characterizing the binding molecule present in the complex with an antibody against the colloidal gold conjugated binding molecule using reverse flow technology.

CO10148450A 2008-05-15 2010-11-25 CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS CO6311040A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200803904-2A SG157244A1 (en) 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus

Publications (1)

Publication Number Publication Date
CO6311040A2 true CO6311040A2 (en) 2011-08-22

Family

ID=41318932

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10148450A CO6311040A2 (en) 2008-05-15 2010-11-25 CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS

Country Status (7)

Country Link
BR (1) BRPI0915291A2 (en)
CO (1) CO6311040A2 (en)
CR (1) CR11836A (en)
EC (1) ECSP10010680A (en)
MX (1) MX2010012363A (en)
SG (1) SG157244A1 (en)
WO (1) WO2009139725A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG165194A1 (en) * 2009-03-20 2010-10-28 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure to hev immunoglobulin a (iga)
CN102393454A (en) * 2011-08-24 2012-03-28 中国检验检疫科学研究院 Colloidal gold test strip for detecting dengue virus antibody and preparation method and application thereof
CA3177572A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
SG10201404571PA (en) * 2014-08-01 2016-03-30 Mp Biomedicals Asia Pacific Pte Ltd Method and kit for detecting a dengue virus infection
EP4082568A1 (en) 2018-09-05 2022-11-02 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2021202992A2 (en) * 2020-04-03 2021-10-07 Lawrence Loomis Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
WO2021216276A1 (en) * 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Rapid, point of care detection of neutralizing antibodies against a virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148066A (en) * 1989-11-06 1991-06-24 Nippon Zeon Co Ltd Membrane for diagnosing virus infectious disease and diagnostic method
EP1005363B1 (en) * 1997-07-31 2006-03-29 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (en) * 1997-08-14 2001-04-06 Pasteur Institut USE OF RECOMBINANT ENVELOPE PROTEINS FOR THE DIAGNOSIS OF DENGUE VIRUS
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates
SG137711A1 (en) * 2006-05-11 2007-12-28 Nat Environment Agency Antigen capture anti-dengue iga elisa (aca-elisa) for the detection of a flavivirus specific antibody

Also Published As

Publication number Publication date
WO2009139725A1 (en) 2009-11-19
MX2010012363A (en) 2011-04-11
CR11836A (en) 2011-06-07
SG157244A1 (en) 2009-12-29
BRPI0915291A2 (en) 2016-02-16
ECSP10010680A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CO6311040A2 (en) CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS
BR112017002209A2 (en) method and kit for detecting a dengue virus infection
SG135990A1 (en) Competitive enzyme linked immunosorbent assay (c-elisa) for the detection of a flavivirus specific antibody
PE20141450A1 (en) LYSILOXIDASE-HOMOLOGY 2 TEST AND METHODS OF USE OF THE SAME
ATE487138T1 (en) SIDEFLOW TEST DEVICE WITH IMPROVED TEST RESULT VALIDITY
AR053948A1 (en) DETECTION OF AN ANCIENT DIANA INDEPENDENTLY FROM THE PRESENCE OR ABSENCE OF A CORRESPONDING THERAPEUTIC ANTIBODY
BRPI0814250B8 (en) device, kit and method for capturing and detecting hookworm antigen
MX2015012823A (en) Hcv antigen-antibody combination assay and methods and compositions for use therein.
TW200740840A (en) Diagnostic test kits
AR066863A1 (en) METHOD FOR DETECTING THE PRESENCE OF THE CALIQUEAMYCIN COMPONENT OF A CALIQUEAMYCIN CARRIER CONJUGATE IN A FLUID SAMPLE AND KIT TO DETERMINE THE CONCENTRATION OF THE CALIQUEAMYCIN PRESENT IN A SAMPLE
AR062852A1 (en) TESTS TO DETECT PROTEINS IN NATIVE STATE AND IDENTIFY COMPOUNDS THAT MODULATE THE STABILITY OF PROTEINS IN NATIVE STATE
BR112014020513A2 (en) Methods and systems for signal amplification of bioassays
AR105379A1 (en) DEVICE FOR DETECTING WICKED PROTEINS AND THEIR METHODS OF USE
NO20083133L (en) Double transdermal analyte sensor composition as well as methods of use thereof
AR112996A1 (en) ANTIBODY-DRUG CONJUGATE EVALUATION METHODS
EA201400571A1 (en) SPECIFIC TO TRANSRESVEROTROL ANTIBODIES AND THEIR APPLICATION
SG165194A1 (en) Point of care test for the detection of exposure to hev immunoglobulin a (iga)
WO2008067007A3 (en) A method for quantitative measurement of thyroid homrones and related antibodies in a serum sample
WO2016069762A3 (en) Subject anti-hcv antibody detection assays employing ns3 capture peptides
RU2012127077A (en) METHOD OF IMMUNOCHROMATOGRAPHIC ANALYSIS FOR SERODIAGNOSTICS
ATE337510T1 (en) O-RING FOR PRESS CONNECTIONS
AR068002A1 (en) A KIT FOR BSH IMMUNO TEST AND METHOD TO MEASURE BSH
WO2009108803A3 (en) Methods and compositions for immunoassays
TH132740B (en) Rapid assay, flow-Laternal immunoassay method For Salmonella
ES2479895B1 (en) Dual recognition immunoassay for antibody detection

Legal Events

Date Code Title Description
FA Application withdrawn